Once again, a new product is launched this week for cancer researchers: RayBio® Cancer Autoantibody Protein Arrays. These arrays are semi-quantitative multiplex protein immunoassays developed for the detection of Cancer related autoantibodies.
Once again, a new product is launched this week for cancer researchers: RayBio® Cancer Autoantibody Protein Arrays. These arrays are semi-quantitative multiplex protein immunoassays developed for the detection of Cancer related autoantibodies.
First at all, a quick reminder… Cytokines play important roles in inflammation, innate immunity, angiogenesis and cell growth. They are involved in a lot of disease processes like cancer, obesity and inflammatory and neurobiological diseases.
The RayBio® Membrane-Based Antibody Arrays (C-Series) are tools for screening and comparing expression levels of many cytokines, growth factors, proteases, soluble receptors, and other proteins in a wide variety of sample type.
After these brief definitions, today I would like to introduce you to a new tool allowing multiple cytokine detection. RayBio C-series Neurobiological Discovery Arrays will help you to measure several factors in inflammation, immunology. This method is very popular and can be used for two species: human and mouse.
Expression signals of validated miRNAs that differentiated pancreato-biliary cancer from non-malignant abnormalities (A), or from cancers of other types (B).
A recent paper by Kojima, M. et al. has found a signature of miRNAs to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
Namely, a combination of eight miRNAs (miR-6075, miR-4294, miR-6880-5p, miR-6799-5p, miR-125a-3p, miR-4530, miR-6836-3p, and miR-4476) achieved a sensitivity, specificity, accuracy and AUC of 80.3%, 97.6%, 91.6% and 0.953, respectively.
In contrast, CA19-9 and CEA gave sensitivities of 65.6% and 40.0%, specificities of 92.9% and 88.6%, and accuracies of 82.1% and 71.8%, respectively, in the same test cohort. This diagnostic index identified 18/21 operable pancreatic cancers and 38/48 operable biliary-tract cancers in the entire cohort.
Chronic Mucosal Inflammation is the hallmark of common airway diseases (ex. Allergic Rhinitis and asthma). Lipoxin B4(LXB4) is an endogenous mucosal protective mediator decreasing such diseases. LXB4 mechanisms of action remain poorly understood.
In a recent paper in Mucosal Immunology (Karra, L. et al. (2015) 8; DOI:10.1038/mi.2014.116), Allergic Rhinitis and asthma murine models have been described to better investigate the role of LXB4 in Mucosal Inflammation. The authors conclude that, in the upper airway, LXB4 significantly decreases nasal mucosal leukocytes and degranulation of Mast Cells (MCs) and Eosinophils. They also show that, in the lower airway, LXB4 significantly decreased airway inflammation, mucus metaplasia, and hyper-responsiveness.